The pharmaceutical film-coating preblend described in this technical introduction is a dry, single-phase gastric-soluble mixture of film-forming polymer, plasticizer, opacifier, and dispersed pigment. The product class is intended for aqueous reconstitution at 10–18 wt% solids and subsequent application to tablets, hard gelatin or hydroxypropyl methylcellulose capsules, and granule or multiparticulate substrates. Gastric solubility in this context means the applied film loses mechanical integrity and permits core wetting in acidic media, typically pH 1.2 to 3.5, rather than functioning as a release barrier. The trade description is not an active pharmaceutical ingredient declaration; the term “API” in the commercial designation must be reconciled with the vendor’s regulatory dossier and the intended excipient role. Model identification is vendor-specific and should be paired with the full trade name on the certificate of analysis, because the polymer-to-plasticizer-to-pigment ratio is lot-specific and matched to the core friability, logo geometry, and color target. Published data for a single universal configuration are limited; application performance must therefore be confirmed on the actual coating line using the final core batch and the intended pan, nozzle, and air-handling train.

Dispersion Rheology and Aqueous Reconstitution Limits

Reconstitution of the dry preblend is performed by adding the powder to purified water USP at 20–25°C under a rotor–stator mixer operating at 1500–3000 rpm. Reverse addition entrains air and can form foam that persists through low-shear transfer. Hydration time of 45 min to 90 min is typical before the dispersion is passed through a 100 mesh sieve. Solids loading below 10 wt% increases evaporative demand, while loading above 18 wt% may produce shear-thinning behavior and nozzle blockage if continuous mixing is interrupted. Final dispersion viscosity, measured by a Brookfield rotational viscometer at 20–25°C and 100 rpm, normally resides between 50 mPa·s and 300 mPa·s; the vendor lot-specific release data define the acceptable band. Deviations in viscosity alter the atomized droplet size distribution. Droplets below approximately 10 µm can dry before impingement and yield spray-dried particles embedded in the film, while droplets above 40 µm can overwet the bed if the pan exhaust capacity is limited.

On a 48 inch fully perforated coating pan equipped with three air-atomizing nozzles, atomizing air pressure is typically set between 0.8 bar and 2.5 bar, with a gun-to-bed distance of 150–250 mm. Inlet air is adjusted to hold exhaust air at 45–55°C and the tablet-bed surface at 38–45°C. These values are not universal; the processing window can narrow to ±3°C when plasticizer content is near the lower end of the range because evaporative cooling competes with film coalescence. Spray rate is ramped from 2–5 g/min per kg core during the initial phase to 8–15 g/min per kg core after logo coverage. Exhaust humidity above 60% RH plasticizes the partially formed film and increases the probability of tablet-to-tablet adhesion, peeling, and intaglio bridging.

The aqueous dispersion should be held under slow agitation during coating. Extended hold beyond 24 h at room temperature is not recommended unless bioburden and viscosity are monitored. Bioburden should be controlled to NMT 100 CFU/mL before the dispersion is considered for oral use; if a sterile claim is required, the limit must be replaced by pre-sterilization filtration through a 0.2 µm membrane and sterility testing according to USP <71>.

What Differentiates the Gastric Preblend from Enteric and Modified-Release Coating Systems?

Enteric preblends commonly contain methacrylic acid–ethyl acrylate copolymer (1:1) or hypromellose phthalate. Those polymers require partial neutralization before spray application to reduce nozzle fouling and film brittleness. The gastric preblend does not require neutralization because it contains no pH-sensitive anionic functionality that precipitates under acidic conditions. The consequence is a shorter reconstitution protocol and lower microbial-growth risk during extended hold times, but the film cannot perform as a delayed-release barrier. Enteric films remain insoluble at pH 1.2 and release at pH 5.5 or 6.8 depending on polymer chemistry; the gastric preblend is designed to fail rapidly at pH 1.2 and should not be substituted into a formulation where gastroresistance is claimed.

Modified-release preblends based on ethylcellulose or ammonio methacrylate copolymer dispersions produce semipermeable films with higher tensile strength and lower water vapor permeability than gastric preblends. In ASTM D882-18 cast-film testing, the gastric system formulated with low-viscosity hypromellose or polyvinyl alcohol–polyethylene glycol graft copolymer commonly exhibits tensile strength in the range 5–15 MPa and elongation at break below 10%. Ethylcellulose-based films may exceed 20 MPa under the same test conditions. The lower tensile strength of the gastric film reduces edge chipping on sharp tablet embossing but limits mechanical protection during metal detection and packaging transit. The higher water vapor permeability is consistent with rapid gastric disintegration but is disadvantageous for moisture-sensitive active ingredients unless a barrier subcoat is applied.

For tablets, the gastric preblend is usually applied to 3–5% weight gain. For multiparticulates and granules, weight gain of 8–15% is typical, and fluid-bed top-spray coating at product temperature 30–40°C is preferred over pan coating to reduce agglomeration and seed adhesion. Hard capsules may require banding before coating to prevent film accumulation at the cap-body seam. For granules, fluid-bed top-spray coating with a Wurster column is used to reduce contact between wet cores. Inlet air temperature is typically 50–70°C, product temperature 30–40°C, and spray rate is adjusted to maintain a droplet size below 15 µm for very fine granules. Agglomeration occurs when the bed dew point rises above the glass transition temperature of the hydrated film for a sufficient period.

These ranges are representative class-level values derived from vendor technical bulletins and compendial excipient monographs; individual product lots require verification.

When a Production Line Converts from Organic-Solvent Coating to Aqueous Gastric Preblend

Conversion from methylene chloride–based or ethanol–water coating to an aqueous gastric preblend removes the need for explosion-proof electrical classification under NFPA 70 and ATEX 1999/92/EC, but it increases the drying enthalpy demand. Water has a latent heat of vaporization of approximately 2257 kJ/kg at 100°C, whereas methylene chloride is near 330 kJ/kg at 40°C. On a pan with 100 kg charge, the same spray rate can more than double the exhaust drying load. The existing air handling unit must be rated for the higher moisture load and dew-point control; otherwise the process time must be extended or the spray rate reduced. Spray drying before impingement occurs when the droplet evaporation time exceeds residence time. Raising atomizing pressure excessively produces smaller droplets, causing dried polymer particles on the core surface. A volume median droplet diameter above 20 µm is commonly targeted for tablet coating to balance drying and film spreading.

When the conversion is executed, the gastric preblend should be trialed first on placebo cores with similar friability, surface energy, and embossment geometry. Core surface energy can be evaluated by sessile-drop contact angle; hydrophobic cores below approximately 35 mN/m may require a pre-wet spray of purified water to improve initial film spreading. The coating pan exhaust temperature, spray rate, atomizing pressure, and pan speed should be recorded in a batch record to establish a reproducible design space. Failure modes observed during conversion include brittle film formation from premature drying, logo bridging from overwetting, and nozzle tip accumulation from interrupted liquid supply.

Although the trade designation includes “Injection” and “Injectable,” the conventional dry gastric preblend is a nonsterile oral solid-dosage coating excipient. Parenteral use requires a sterilized version supported by a certificate of sterility demonstrating SAL 10^-6 under ISO 11137 or ISO 17665, or aseptic filtration of the aqueous dispersion through a 0.2 µm sterilizing-grade membrane. Standard pan and fluid-bed coating are not terminal sterilization steps. If a coated intermediate is intended for injection, the entire manufacturing train, including purified water, vessels, compressed air, and coating equipment, must meet current good manufacturing practice under 21 CFR 210/211 and cleanroom classification under ISO 14644-1. Published data for this exact gastric preblend in injectable coating applications are limited; oral solid-dose process behavior should not be extrapolated to parenteral dosage forms without a separate regulatory filing.

For oral solid-dose use, tablet core friability should be controlled below 0.5% by USP <1217> before coating to prevent edge erosion during pan rotation. The preblend is not compatible with amine-based liquid colorants that can cause premature polymer crosslinking or pH drift in the dispersion. Storage of the dry preblend should follow the vendor’s label; opened containers should be resealed under nitrogen when sustained humidity exceeds 60% RH.